ALKS Q3 2019 Earnings — Alkermes plc Revenue & Financial Results | Market Cap Arena

ALKSAlkermes plc

$5B

Q3 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$255M+2.6% YoY

Gross Profit

$213M83.4% margin

Operating Income

-$54M-21.0% margin

Net Income

-$53M-20.7% margin

EPS (Diluted)

$-0.34

QoQ Revenue Growth

-8.8%

Cash Flow

Operating Cash Flow

$31M

Free Cash Flow

$12M

Stock-Based Comp.

$27M

Balance Sheet

Total Assets

$1.8B

Total Liabilities

$690M

Stockholders' Equity

$1.1B

Cash & Equivalents

$261M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$255M	$249M	+2.6%
Gross Profit	$213M	$209M	+1.7%
Operating Income	-$54M	-$37M	-44.3%
Net Income	-$53M	-$34M	-53.5%

Revenue Segments

Product

$139M50%

Vivitrol

$85M31%

Aristada

$54M19%